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Background: Axonal pathology might constitute one of the earliest manifestations of Alzheimer disease. Axonal
dystrophies were observed in Alzheimer’s patients and transgenic models at early ages. These axonal dystrophies
could reflect the disruption of axonal transport and the accumulation of multiple vesicles at local points. It has
been also proposed that dystrophies might interfere with normal intracellular proteolysis. In this work, we have
investigated the progression of the hippocampal pathology and the possible implication in Abeta production in
young (6 months) and aged (18 months) PS1(M146L)/APP(751sl) transgenic mice.
Results: Our data demonstrated the existence of a progressive, age-dependent, formation of axonal dystrophies,
mainly located in contact with congophilic Abeta deposition, which exhibited tau and neurofilament
hyperphosphorylation. This progressive pathology was paralleled with decreased expression of the motor proteins
kinesin and dynein. Furthermore, we also observed an early decrease in the activity of cathepsins B and D,
progressing to a deep inhibition of these lysosomal proteases at late ages. This lysosomal impairment could be
responsible for the accumulation of LC3-II and ubiquitinated proteins within axonal dystrophies. We have also
investigated the repercussion of these deficiencies on the APP metabolism. Our data demonstrated the existence of
an increase in the amyloidogenic pathway, which was reflected by the accumulation of hAPPfl, C99 fragment,
intracellular Abeta in parallel with an increase in BACE and gamma-secretase activities. In vitro experiments, using
APPswe transfected N2a cells, demonstrated that any imbalance on the proteolytic systems reproduced the in vivo
alterations in APP metabolism. Finally, our data also demonstrated that Abeta peptides were preferentially
accumulated in isolated synaptosomes.
Conclusion: A progressive age-dependent cytoskeletal pathology along with a reduction of lysosomal and, in
minor extent, proteasomal activity could be directly implicated in the progressive accumulation of APP derived
fragments (and Abeta peptides) in parallel with the increase of BACE-1 and gamma-secretase activities. This retard
in the APP metabolism seemed to be directly implicated in the synaptic Abeta accumulation and, in consequence,
in the pathology progression between synaptically connected regions.
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Alzheimer´s disease (AD) is a proteinopathy character-
ized by the accumulation of aggregated extracellular
amyloid-beta (Abeta, Aβ) peptides and intracellular
hyperphosphorylated tau (revised in [1]). Concomitant
with appearance of extracellular Abeta deposits, another
central pathological feature of the disease is the early
formation of amyloid plaque-associated neuritic changes
in the form of dystrophic neurites, together with a se-
lective loss of connections and neuronal groups. Dys-
trophic neurites, defined as thickened or irregular
neuronal processes, are considered to be expression of a
widespread alteration of the neuronal cytoskeleton. In
AD, dystrophic axons are particularly abundant in the
hippocampal fiber systems originating from the subicu-
lum, CA1, and the entorhinal cortex [2]. However the
exact molecular mechanisms underlying the pathogen-
esis of AD remain to be elucidated.
Dystrophic neurites were characterized by the pres-
ence of numerous vesicles of multiple origins [3,4]. Sev-
eral lines of investigation support the notion that
defective autophagy process, a cellular catabolic mech-
anism essential for degradation of aggregated proteins
and organelles, significantly contributes to AD patho-
genesis [5-8]. Interestingly, autophagic compartments
have been reported to participate in APP processing and
Aβ peptides production [9].
Abeta peptides, cytotoxic in their oligomeric state [10-13]
derive from the sequential cleavage of APP by beta- and
gamma-secretases [14,15]. Although the exact intracel-
lular localization of APP processing is unknown, the
autophagic and endocytic pathways could be both
involved in precursor protein (APP) processing and
Abeta generation. In this sense, BACE-1 and gamma-
secretase complex have been detected in many cellular
locations, including early and late endosomes [16],
autophagic vacuoles [17-19] and lysosomes [20]. On the
other hand, the Abeta degradation, in vivo, could be
mediated by several proteases, as neprilysin, IDE, and
several cathepsins as B, D and E [21]. Abnormal proces-
sing of APP or Abeta accumulation in AD could be
related to several mechanisms, including excessive pro-
duction, abnormalities in transport, alteration of autop-
hagic and endosomal pathways, and deficits in its
degradation through the lysosome or the ubiquitin-
proteasome system (UPS) [22-24]. In fact, accumulation
of autophagic vacuoles (AVs) has been observed in
brains from AD patients [3,19] and in PS1/APP mice
after Abeta deposition [17,19,25]. Moreover, the AVs
were principally accumulated within dystrophies and
could reflect impairment in AVs clearance in AD brains
[5]. In this sense it has been reported that enhancing
lysosomal cathepsin activity ameliorates Abeta toxicity
[26] and restoring the autophagy-lysosomal pathway (bydeletion of cystatin B) reduced amyloid load and res-
cued memory performance [9].
In the present work we investigated how the possible
age-related relationship between aberrant Abeta gener-
ation and dysfunctions in axonal cytoskeleton as well as
in lysosomal and proteasomal systems, manifested in
our PS1/APP AD model. We proposed that the decrease
in lysosomal proteolytic activities was implicated in
increased Abeta production. Abnormal accumulation of
Abeta could aggravate the axonal and cytoskeleton ab-
normalities linked to the pathology of AD.
Results
The age-dependent increase of neuritic dystrophies was
paralleled by phosphorylation of cytoskeletal proteins
and decrease in motor proteins
APP-positive dystrophic neurites represented an early
pathology in our PS1/APP model [17]. These dystro-
phies were of axonal origin and, at early ages, were
located exclusively surrounding congophilic Abeta pla-
ques. It was also known that Abeta load increased with
aging in this and most AD models [27]. Thus, we have
first evaluated the progression of the APP-positive
dystrophy formation from early (4–6 months) to late
(12–18 months) ages. As expected, the number of
APP-positive dystrophies, surrounding Abeta plaques,
increased significantly in 12–18 month cohort (Figure 1A),
paralleling the increase in plaque size and number
(Figure 1A and [17]). Furthermore, according with pre-
vious data, the dystrophic neurites were predominantly
concentrated surrounding the congophilic Abeta plaques
at all ages.
The presence of aberrant hyperphosphorylated cyto-
skeletal proteins is one of the major pathological hall-
marks of AD [28]. Furthermore, hyperphosphorylated
neurofilaments and tau seemed to overlap with senile
plaques in AD patients and models (unpublished data,
see also [17,28,29]). Thus, hyperphosphorylated cytoskel-
etal proteins could also be implicated in the progression
of the pathology in our PS1/APP model. To determine
this possibility, we tested the neurofilaments (using SMI
antibodies) and tau phosphorylation (AT8 and AT100
epitopes) in 6- and 18 months PS1/APP. As we
described previously [17], 6-month-old PS1/APP mice
displayed only minor modifications. In fact, as compared
with age-matched WT mice, neurofilament (heavy and
medium chains; H, M) phosphorylation (calculated as
ratio between phospho and non-phosphorylated neurofi-
lament) exhibited no apparent modifications at this age
(see Figure 1B). Only the levels of AT8 epitope were
slightly but significantly increased. However, 18-month-
old PS1/APP mice displayed advance cytoskeletal path-
ology. As shown (Figure 1B), neurofilament heavy and
medium chains were hyperphosphorylated (mostly due
Figure 1 Aged-dependent increase of the hippocampal axonal pathology in PS1/APP mice. A) APP-immunolabeled CA1 sections with
Congo red at 6 (left) and 18 (right) months of age showing the age-dependent increase in the dystrophic neurite pathology. Dystrophies were
concentrated surrounding Abeta plaques (insets in a1 and a2 show higher magnifications). The quantitative analysis of plaque-associated
dystrophies demonstrated a significant increase in aged mice. B) Representative western blots (n=5/age/group) for phosphorylated (upper panel)
and non-phosphorylated (lower panel) neurofilament (SMI antibodies). Bands corresponding to high (H) and medium (M) chains were indicated.
Quantitative analysis revealed an increase in the phosphorylated vs non-phosphorylated H and M neurofilaments in aged PS1/APP mice. No
changes were observed in 6 month-old PS1/APP or WT mice. C) Tau phosphorylation was determined by western blots using AT8 (upper panel),
AT100 (medium panel) and tau (lower panel) antibodies at 6 and 18 months of age (n=5/age/group). Graph showed the quantitative analysis of
AT8 western blots. Due to the lack of immunoreactivity in WT and 6 months PS1/APP mice, the AT100 signal could not be quantified. A
prominent increase in AT100 epitope (absent in other conditions) was observed in 18 month-old transgenic mice. D) AT8 immunostaining
revealed that phospho-tau concentrated principally in dystrophies around congophilic plaques. E) Western blots and quantitative analysis (n=5/
age/group) of kinesin (upper panel) and dynein (lower panel) expression. Both motor proteins decreased in PS1/APP mice. So, stratum oriens; sp,
stratum pyramidale; sr, stratum radiatum. Scale bars: 200 μm (a1/a2), 10 μm (inset a1), 20 μm (inset a2), 20 μm (D).
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agreement with this observation, both AT8 and, more
prominently, AT100 tau phosphoepitopes (Figure 1C)
were increased in 18 month-old PS1/APP. The presence
of hyperphosphorylated tau was further confirmed by
immunohistochemistry. Tau-reactive (AT8) dystrophic
neurites, localized surrounding amyloid plaques, were
detected since early ages (Figure 1D).
To further evaluate whether microtubule vesicular
transport might be compromised in PS1/APP mice, wehave assessed the levels of kinesin-1 and dynein motor
proteins. As previously reported [17], 6 month-old PS1/
APP mice showed a modest reduction on both proteins
and, in accordance with the advance pathology, the
levels of both motor proteins were dramatically reduced
in 18 months PS1/APP mice (Figure 1E).
These data confirmed and extended our previous ob-
servation in this model, at early ages, and demonstrated
the existence of a clear age-dependent axonal pathology
implicating cytoskeletal and motor proteins.
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was associated to an impairment of proteolysis
mechanisms
It has been reported that axonal dystrophy could be pro-
duced by inhibition of the lysosomal proteolysis [30,31]
or by axonal transport deficiencies [32]. However, axonal
transport was also essential for the correct lysosomal
maturation and intracellular protein degradation [33].
Thus, the formation and the age-dependent increase in
neuritic dystrophies could be cause or consequence of a
progressive reduction of the intracellular proteolytic pro-
cesses. Theoretically, an impairment on either proteaso-
mal and/or autophagic/lysosomal route, in the PS1/APP
model, should be reflected by the accumulation of ubi-
quitinated proteins and/or the autophagic maker LC3-II.
In fact, our data (Figures 2A and B) clearly demonstrated
the existence of a marked and early accumulation of
both ubiquitinated proteins and LC3-II in hippocampal
samples from PS1/APP mice. This accumulation was
observed since early ages (6 months of age), increased
significantly in aged PS1/APP mice (18 months) and was
not observed at 2 months of age, before plaque depos-
ition (not shown). On the contrary, WT mice displayed
absolutely no changes at these ages. These data were fur-
ther confirmed by immunohistochemistry experiments.
As shown, (Figure 2C, c1 to c6), the LC3 immunoreac-
tivity was principally located in the somata and apical
dendrites of principal neurons whereas ubiquitin immu-
nostaining (Figure 2D, d1 to d6) was mainly located at
the cell bodies (see Figure 2D, d2 inset). Furthermore,
most (if not all) Abeta plaques (stained with Congo Red)
were surrounded by dystrophies, LC3 or ubiquitin
immunopositive, both at 6 months and more patently at
18 months of age.
Although the accumulation of LC3-II could reflect
both, induction in the autophagy route or decrease in
the autophagosome degradation, the presence of ubiqui-
tinated proteins in a similar localization of LC3, surround-
ing Abeta plaques, strongly suggested the existence of a
decrease in autophagosome degradation. Among differ-
ent causes, the decrease in autophagosome degradation
could reflect a decrease in the lysosomal activity. Thus,
we next evaluated the lysosomal and proteasomal activ-
ity by determining the cathepsins, B and D, activities
and the proteasomal chymotrypsin-like activity. As
shown (Figure 2E), both cathepsin B and D activities
decreased since relatively early ages. Young (6 months)
PS1/APP displayed a consistent (−39.21±18.84%; n= 5,
p<0.05; -44.15±13.51%, n=3, p<0.05; for cathepsin B
and D, respectively) decrease (as compared with age
matched WT) whereas 18 month-old PS1/APP mice
displayed a further diminution (−72.50±4.2%; n=4,
p<0.05; -55.45±6.7, n=3, p<0.05, respectively). No changes
were observed before plaque deposition (at 2 month-old,not shown). On the other hand, the proteasomal activity
(Figure 2F) also displayed a slight, and not significant
diminution at 6-months (−20.4±12.3%, n=4) followed by
a more pronounced inhibition in aged PS1/APP mice
(−45.5±15.6%; n=4; p<0.05). No differences between WT
and PS1/APP were observed before the plaque deposition
(2 months of age, not shown) and no inhibition was
observed in 18 months WT mice.
Consistent with the decrease in lysosomal activity, we
also observed a significant reduction in the mature
forms of both cathepsins B and D in PS1/APP mice
(Figures 3A and B) and an accumulation of the lyso-
somal protein lamp 1 (Figures 3C),at 6 and 18 months.
Furthermore, this accumulation of lysosomal proteins
seemed to be localized in dystrophies surrounding Abeta
plaques, as demonstrated by immunohistochemistry ana-
lysis of lamp 2 protein (Figure 3D). These data revealed
the existence of a lysosomal dysfunction in PS1/APP
mice after plaque deposition. In this sense, it has been
recently reported [6] that PS1 mutations affected the
correct maturation of the V0a1 subunit of the vATP-ase
and the lysosomal acidification. However, in our model,
we observed an accumulation of the mature form of
V0a1 protein (Figure 3E), similar to lamp 1 protein
(compare Figures 3C and E). Furthermore, 6-month-old
homozygous PS1M146L transgenic mice displayed no
alterations on cathepsin B activity (not shown).
The amyloidogenic APP processing and both BACE-1 and
gamma-secretase activities were increased in aged PS1/
APP mice
Data so far demonstrated the existence of a progressive
age-dependent neuritic (probably axonal) pathology in
the PS1/APP model that affected the intracellular pro-
teolytic systems. We next evaluated whether this pro-
gressive pathology could affect the amyloidogenic APP
processing. As shown (Figure 4A), the mature hAPPfl
(visualized as two bands, corresponding with the mature
and immature forms of the transgenic hAPP) signifi-
cantly increased in the hippocampus of 18 month tg
mice, as compared with 6 month-old animals (2.01±0.04;
n=6; p<0.05), Also, a significant increase in the ratio
mature/immature form of the hAPP was observed (data
not shown). However, no differences in mRNA expres-
sion of the transgenic hAPP were detected between 2
and 18 months (data were normalized to the expression
levels observed in 6 months PS1/APP, n=6 for each age,
1.12±0.15, 1.0±0.27, 1.33±0.29 and 1.23±0.48 for 2, 6,
12 and 18 month PS1/APP, respectively).
The APP proteolytic fragments C83 (alpha-CTF) and
C99 (beta-CTF) are products from alpha- or beta-
secretase processing, respectively, and substrates for
gamma-secretase complex. As also shown in Figure 4A,
the levels of C99 showed a clear age-dependent increase,
Figure 2 Impairment of lysosomal and proteasomal protein-degradation in PS1/APP mice. A and B; Representative western blots and
quantitative analysis (n=5 for each age and animal group) of the autophagic vesicle marker LC3 (A) and ubiquitinated proteins (B) performed
using the same protein samples. An age-dependent accumulation of both LC3-II and ubiquitinated proteins were observed exclusively in PS1/
APP samples. (C-D) Three different magnifications of LC3- (C) or ubiquitin- (D) immunolabeled hippocampal sections (counterstained with Congo
red for Abeta plaques) of 6 and 18 months of age PS1/APP mice corroborated the age-dependent accumulation of both markers, associated with
dystrophic neurites surrounding amyloid plaques (c1, c4, d1 and d4, panoramic views of immunostained hippocampus; c2, c5, d2 and d5, CA1
region, arrows indicate plaques covered by immunopositive dystrophies and inset in d2 shows immunolabeling in the pyramidal layer somata;
c3, c6, d3 and d6, representative image of a congophilic plaque surrounded by dystrophic neurites, arrows point to positive dystrophies around a
congophilic plaque indicated by an asterisk). Assays of lysosomal cathepsin B or D (E) and proteasomal chymotrypsin-like (F) enzymatic activities
demonstrated the existence of a pronounced decrease in cathepsin B and D activities (since early ages in PS1/APP), whereas proteasome was
affected only in aged tg mice. CA1, hippocampal subfield; DG, dentate gyrus; so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum; slm,
stratum lacunoso-moleculare. Scale bars: 500 μm (c1/c4, d1/d4), 100 μm (c2/c5, d2/d5), 10 μm (c3/c5, d3/d5); 50 μm (d2, inset).
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were low (respect to C99) and remained practically un-
altered during aging (see also Figure 5). Together with
the accumulation of APP and APP-fragments, we also
observed an increase in the levels of both BACE-1 and
PS1 proteins. As shown, Figure 4B, the mature (and im-
mature) form of BACE-1 was increased in 18-month-old
PS1/APP mice (as compared with 6 months) whereas no
differences in mRNA levels were observed (data werenormalized by the expression of 6-month-old WT mice,
n=5 for each age and genotype: 6 months: 1.00±0.08
vs 0.88±0.24; 12 months: 1.39±.19 vs 1.10±0.12; 18
months: 1.29±0.20 vs 1.33±0.27; for WT and PS1/APP,
respectively). As expected, BACE-1 was preferentially
accumulated within dystrophies, surrounding Abeta
plaques (Figure 4C). Furthermore, this alteration in
BACE-1 level was also reflected by a higher BACE-1
enzymatic activity (Figure 4E). In parallel with these
Figure 3 The mature forms of cathepsin B and D decreased whereas Lamp1, Lamp2 and V0a1 proton pump subunit accumulated in
PS1/APP mice hippocampus. (A-B) Western blots and quantitative analysis (n=5 for each age and animal group) of cathepsin B (A) and D (B)
showed the existence of a significant decrease in the mature forms of both proteins. This decrease was observed exclusively in PS1/APP
transgenic mice at both ages tested (6 and 18 months). C-D) Same mice model accumulated Lamp1 (tested by western blot, C, n=3) or Lamp2
(tested by immunohistochemistry at 6 and 18 months of age). Lamp2 immunolabeled sections of 6 (d1) and 18 (d2) month-old PS1/APP mice
counterstained with Congo red for fibrillar amyloid plaques revealed Lamp2 labeling associated to dystrophic neurites surrounding amyloid
plaques (arrows) at both ages that increased with age. In WT mice (d3 and d4, for 6 and 18 months respectively) Lamp-2 immunostaining was
associated to cell somata and neuropile. No dystrophies were detected in control samples. E) Representative western blot and quantitative
analysis (n=5 for each age and animal group) of V0a1 proton pump subunit in samples from 6 and 18 month-old WT and PS1/APP mice. Both,
the mature and immature forms of V0a1 seemed to be accumulated, although not significantly, in 6 and 18 months of age PS1/APP mice. CA1,
hippocampal subfield; DG, dentate gyrus; so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum. Scale bars: 500 μm (D), 25 μm
(insets in d1 and d2).
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undetectable in WT and at early ages in PS1/APP mice,
Figure 4D) were also accumulated in aged PS1/APP
mice (Figure 4D), in absence of variation in the trans-
gene expression (data were normalized to expression
levels detected in 6 months PS1/APP, n=6 for each age,
1.06±0.45, 1.0±0.69, 1.33±0.62 and 1.03±0.82 for 2, 6, 12
and 18 month PS1/APP, respectively). Although gamma-
secretase is a multimeric protein and the increase in a
single subunit could not directly reflect a parallel incre-
ment in the mature complex, it is of note that PS1-
terminal fragments were exclusively generated when
PS1fl was incorporated into the mature complex (see[34]). Thus, these data were consistent with an age-
dependent increase in gamma-secretase. In fact, the
gamma-secretase activity, determined as the rate of AICD
production using fresh membranes isolated from different
ages (in consequence, the substrate was the endogenous
APP-CTF fragments, presented at each age) displayed a
consistent increase in the aged PS1/APP samples
(Figure 4F). It should be noted that, under these experi-
mental conditions, we cannot discriminate if the increase
in gamma-secretase activity was reflecting the accumula-
tion of PS1-ctf or just an increase in substrate (C99 frag-
ment, predominantly). Independently, the aged PS1/APP
mice displayed an increased C99 processing capacity.
Figure 4 Increased amyloidogenic processing of APP in aged PS1/APP hippocampus. A) Representative western blots (n=4 for each age
and animal group) for full-length APP (hAPPfl) (upper panel) and, APP-C terminal fragments (C99 and C83; middle panel) in 6, 12 and 18 month-
old PS1/APP hippocampal samples. Quantitative analysis showed a significant increase in C99 from 6 to 18 months. APPfl also displayed a
moderate (but significant) accumulation at 18 month-old. The amyloidogenic route was evaluated by testing the expression of BACE-1 (by
western (B), n=5; and immunohistochermistry (C), n=3) and PS1 (n=6) (D) proteins. Dystrophic neurites surrounding plaques were positive for
BACE-1 antibody. The enzymatic activities of BACE-1 (n=3) (E) and gamma-secretase (n=6) (F) were also assayed. Inset in panel F showed the
accumulation of soluble AICD after 2 hours of incubation (at 37°C), in absence (minus) and in presence (plus) of 100 μM of the gamma-secretase
inhibitor L-685-458, demonstrating that AICD production was dependent of the gamma-secretase activity. As shown, 18 month-old PS1/APP mice
displayed an accumulation of both BACE-1 and PS1 (CTF fragment and full length) proteins paralleled by an increase in the corresponding
enzymatic activities. Scale bar: 50 μm.
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Abeta accumulation in N2aAPPswe cells
We next evaluated, in vitro using APPSwedish trans-
fected N2a cells [35], whether the APP metabolism was
indeed affected by the inhibition of the intracellular pro-
teolysis. For these experiments, the lysosomal or protea-
somal/lysosomal activities were inhibited by the addition
of Chloroquine (10 μM) or MG132 (5 μM). As expected,
both lysosomal and/or proteasomal inhibition produced
the accumulation of ubiquitinated proteins and the
autophagosomal marker LC3-II (Figure 5A). Using thesame protein extracts, we next tested whether the inhib-
ition of proteasomes and/or lysosomes was reflected by
alterations of the APP metabolism. As shown, both inhi-
bitors produced a clear accumulation of APP-CTFs in
APP N2a cells. In fact, C99 fragment and, more relevant,
intracellular monomeric Abeta were accumulated after
either treatment (Figure 5B). Furthermore, we also
observed a parallel accumulation of BACE-1 and PS1-cft
protein (Figure 5C). Therefore, these in vitro experi-
ments demonstrated that the inhibition of lysosomal
or proteasomal degradation processes produced the
Figure 5 In vitro inhibition of either lysosomal and/or proteasomal activities induced the amyloidogenic APP processing in N2a-
APPswe cultures. A) The inhibition of proteasomal/lysosomal (MG132) or lysosomal (Chloroquine) activities produced the accumulation of both
ubiquitinated proteins (upper panel) and LC3-II autophagosomal marker (middle panel). Graphs showed the quantitative data of three different
experiments using three different N2aAPPswe cultures. B) Using the same protein samples as in (A), we analyzed the effect of either inhibitor on
the APP-CTF processing (upper western) and intracellular Abeta accumulation (lower western). As also shown quantitatively in graphs, either
treatment produced the increase in the APP processing and the intracellular Abeta accumulation. C) In parallel, the expression of BACE-1 and
PS1-ctf was also tested. As showed quantitatively, after 24h of treatment, both BACE-1 and PS1-cft were significantly accumulated in N2aAPPswe cells.
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in parallel with BACE-1 and PS1-ctf proteins. These data
demonstrated that any misbalance in the correct intra-
cellular proteolysis could induce the accumulation of
APP products and, in consequence, increased the pro-
duction of Abeta peptide.
Age-dependent increase in Abeta accumulation in
isolated presynaptic terminals (synaptosomes)
Finally, we also tested whether the observed age-
dependent deficiencies in cytoskeletal proteins, lyso-
somal activity and APP-metabolism were reflected by
modification of the APP fragment distribution inisolated synaptosomes. If the neuritic pathology in this
model was predominantly, although not exclusive, of
axonal origin, the observed modifications should pro-
duce the accumulation of APP-derived peptides (includ-
ing Abeta) at the presynaptic terminals. In fact, we have
recently reported the existence of presynaptic terminals
containing multiple autophagic vesicles in PS1/APP mice
[17]. To test this possibility, the homogenates were frac-
tionated into microsomal and synaptosomal fractions.
The microsomal fraction contained a heterogeneous
population of vesicles of different origins whereas synap-
tosomes were principally enriched in presynaptic
terminals.
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as a marker of autophagosomes, between microsomes
and synaptosomes. As shown (Figure 6A, a1), in WT
mice the LC3-II was abundant in microsomes whereas it
was scarce in synaptosomes at any age tested (see also
[17]). As expected, the LC3-II levels were higher in PS1/
APP mice, as compared with WT, and increased with
age in both fractions (Figures 6A and B). Thus, these
data indicated the accumulation of autophagic vesicles
at the presynapses [17] and also corroborated the exist-
ence of transport defects in PS1/APP mice.
We next analyzed the distribution of APP CTFs (C99
and C83) and Abeta between both fractions (Figure 6A,
a2-4). Although the level of C99 increased clearly with
age (in agreement with our previous data), the C99 con-
tent was patently higher in microsomes than in the
synapsomal fraction. This preferential distribution wasFigure 6 Monomeric Abeta was preferentially accumulated in isolated
C99 fragment preferentially localized in microsomes. A) Microsomal an
and PS1/APP mice. Using these samples, we tested the distribution of LC3-
monomeric Abeta peptide (a3 and a4 for a longer exposure). ATP-synthase
loading. Quantitative analysis of western blots demonstrated the age-depe
6 month WT mice) (B) and C99 (as compared with 6-month-old PS1/APP m
preferentially accumulated in the synaptosomal fractions (D). These experim
the intrasynaptosomal origin of the monomeric Abeta. The tissue from a 1
(control) or in presence of 0.5% CHAPS + 0.5% DOC, and synaptosomes we
membranes avoided the Abeta flotation on gradients (upper panels). On th
in absence (minus) of presence (plus) of synthetic Abeta42 and the synapto
homogenization.in agreement with the accumulation of BACE-1 in dys-
trophic neurites (Figure 4C) and the relative abundance
of BACE-1 in microsomes (vs synaptosomes, data not
shown). However, in spite of the large C99 accumula-
tion, the monomeric Abeta peptide was scarce in micro-
somes and was preferentially accumulated at the
synaptosomal fractions. It is noteworthy that, at early ages,
synaptosomes accumulated low amount of monomeric
Abeta (see Figures 6 a3, a4, D and E), whereas, at late ages,
the monomeric Abeta peptide was highly concentrated at
the synaptosomal fractions (63.6±7.5 fold as compared
with 6 months, n=4; Figure 5D).
It could be argued that synaptosomal Abeta were of
extracellular origin, due to contamination with plaques or
by internalization during homogenization. To ascertain
the intrasynaptosomal origin we have first tested whether
the Abeta in the synaptosomal fractions was due to plaquesynaptosomal fraction, from aged PS1/APP mice, whereas APP-
d synaptosomal fractions were isolated from 6, 12 and 18 months WT
II autophagosomal marker (a1), the APP-CTF fragments (a2) and the
and b-actin were used as control of synapsomal integrity and protein
ndent accumulation of LC3-II (compared with the respective fraction in
icrosomes) (C) in microsomal fractions. The monomeric Abeta was
ents were repeated four times. E) Control experiments demonstrating
2 month-old PS1/APP mice was divided, homogenized in absence
re isolated by Ficoll gradients. As shown, the disruption of cell
e other hand, tissue from 6 month-old WT mice were homogenized
somes were isolated. No Abeta were compartmentalized during
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disruption of cellular membranes and the formation of
synaptosomes, by homogenization of the tissue in presence
of mild detergents (CHAPS plus deoxycholate), completely
avoided the presence of Abeta on the synaptosomal frac-
tions of the Ficoll-gradients. Second, the possible extracel-
lular origin of Abeta, due to its compartmentalization on
synaptosomes during homogenization, was tested by add-
ing synthetic monomeric Abeta42 to WT samples in the
homogenization buffer. As shown, Figure 6E lower panel,
the synthetic Abeta was not recovered on the synaptoso-
mal fractions of WT mice whereas it was clearly detectable
on the soluble fractions. These control experiments
demonstrated the intrasynaptosomal origin of Abeta.
Discussion
In this work, we studied the progression of hippocampal
neuronal pathology, in the PS1M146L/APP751SL model,
that connects cytoskeleton and protein degradation dys-
function with dystrophy formation and synaptic Abeta
production. As we reported previously, this model dis-
played the formation of axonal dystrophies, associated to
extracellular Abeta deposition since early ages [17].
These dystrophies accumulated numerous vesicles of,
among different origins, autophagic/lysosomal nature.
Also, the axonal pathology was associated with the pres-
ence of aberrant presynaptic terminals in close proximity
to Abeta plaques. In agreement with others [36-38] we
observed that extracellular Abeta, probably by increasing
the local calcium concentration, might produce cytoskel-
etal abnormalities that could induce transport defects
(see also [39-43]). In fact, data presented in this work
demonstrated the existence of a progressive increase in
neurofilaments and tau hyperphosphorylation (SMI31,
AT8 and AT100 epitopes). This increase was prevalently
observed in dystrophies, surrounding the Abeta plaques.
In conjunction with this apparent cytoskeletal dysfunc-
tion, we also observed a decrease in the levels of kinesin
and dynein motor proteins. Taken together, these data
strongly suggest the existence of a progressive, age-
dependent, disorganization of the axonal cytoskeleton,
which could impair the normal axonal transport, at local
points in contact with extracellular Abeta deposits, (see
also [25,43]). Furthermore, our data also demonstrated
the accumulation of LC3-II and ubiquitinated proteins,
principally at dystrophies. Whereas these observations
could be interpreted as a simple accumulation of autop-
hagosomes/lysosomes due to transport defects, our data
also demonstrated the existence of a marked inhibition
of the intracellular proteolytic activities. In fact, we
observed a profound decrease in the cathepsin B and D
activities and, in a minor extent, the proteasomal
chymotrypsin activity. In parallel, we also observed a re-
duction in the mature forms of both cathepsins B and Din PS1/APP samples. The reasons that determined this
marked and early proteolytic inhibition are unknown. It
has been proposed that FAD mutations in PS1 impaired
the maturation of V0a1 subunit of the vATP-ase [6].
However, as mentioned (see results), in our model, the
V0a1 subunit displayed no apparent defects on its mat-
uration. Furthermore, 6-month-old PS1M146L trans-
genic mice displayed no variations on cathepsin B
activity. Thus, the observed decrease in cathepsin B
and D activities seemed to be independent of the pro-
ton pump maturation (see also [44]). Nevertheless, our
data were indeed compatible with defects on lyso-
somal acidification and/or maturation. In this sense, it
has been also proposed that axonal transport was cru-
cial for lysosomal maturation and function [33]. Thus,
in our AD model, the cytoskeletal disorganization
(probably mediated by extracellular Abeta and calcium
misbalance) could also impair the lysosomal matur-
ation (reflected by a decrease in the mature forms
of both cathepsins tested) and, in consequence, the
proteolytic function (decrease in the cathepsin activ-
ities). Further experiments should be done to ascertain
this point.
We also analyzed the consequences of this neuritic
pathology on APP processing and Abeta generation.
In this sense, the overexpression of cathepsin B [45],
the enhancement of cathepsin activities [9] or the
positive lysosomal modulation [26] reduced the Abeta
accumulation, the synaptic deficiencies and restored
the cognitive function in transgenic mice. Thus, the
progressive decrease of cathepsin activities and, in a
minor extent, proteasomal activity, observed in our
model, could be paralleled by an increase in the amy-
loidogenic APP processing. In fact, the observed age-
dependent accumulation of hAPPfl and C99, together
with the increase in BACE-1 and PS1-ctf proteins and
their enzymatic activities, confirmed this proposition.
Furthermore, our in vitro experiments also corrobo-
rated the rapid and progressive accumulation of APP
derived C-terminal fragments, intracellular Abeta and
both BACE-1 and PS1-ctf proteins after lysosomal
and/or proteasomal inhibition (see also [46,47]).
Therefore, based on these data, it is tempting to
speculate that the formation of axonal dystrophies,
probably due to the presence of extracellular Abeta
[48], might produce a decrease in the intracellular
proteolysis. This was paralleled by the accumulation
of APP derived fragments inducing, in consequence,
the production of higher amount of Abeta peptides
(see also [49]). This self-progressing pathological sce-
nario could be implicated in the progressive increase
of Abeta and BACE-1 observed in AD patients (data
not shown; see also [50]) and in the expansion of the
pathology (see below).
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preferential accumulation of Abeta peptides in isolated
synaptosomal fractions. Whereas this preferential accu-
mulation could reflect the high gamma-secretase activity
at the presynaptic terminals (data not shown but see
[51]), these data also indicated that Abeta peptides were
produced in compartment(s) different to, or in addition
to, the autophagic vesicles [52]. This proposition was
based on the observation that LC3-II, an autophagic
marker, was preferentially concentrated in the micro-
somal fractions and it was scarce in synaptosomes. Al-
though autophagic vesicles were indeed concentrated in
pathological presynaptic terminals [17], the clear dispro-
portion between LC3-II and Abeta in microsomes and
synaptosomes, at all ages tested, strongly indicated a dif-
ferent compartmentalization. In this sense, it has been
recently proposed that Abeta was synaptically produced
and secreted from endosomal compartment [53]. Inde-
pendently of the intracellular compartment, the synaptic
production of Abeta peptides, observed in this work,
could be implicated in the synaptic dysfunction in AD
patients and in the pathological progression between
synaptically connected areas. In this sense, it is widely
accepted that the severity of the disease correlated better
with the synaptic dysfunction rather than the plaque
load. Thus, the age-dependent accumulation and, prob-
ably, release of Abeta peptides by presynapses could be
directly implicated in the dendritic spine alterations
observed in AD patients and in AD models. Further-
more, recent publications have been highlight the pro-
gression of Abeta [54,55] and tau [56,57] pathology
between synaptically connected regions. In this sense,
we have also reported the existence of a preferential
Abeta deposition, microglial activation and neurodegen-
eration of principal neurons in layers V-VI of the entorh-
inal cortex [58]. However, these particular pyramidal
cells did not express the transgenic hAPP and, in conse-
quence, did not produce Abeta peptides. Thus, the pre-
synaptic accumulation of Abeta peptides, reported here,
might be implicated in the Abeta deposition and patho-
logical spreading from Abeta producing region/layer into
other brain regions.
In sum, our data demonstrated the existence of a pro-
gressive, age-dependent, cytoskeletal pathology (probably
due to the extracellular Abeta deposition) that could be
implicated in a reduction of the intracellular proteolyti-
cal processes. This impairment was associated to a pro-
gressive accumulation of APP derived fragments (and
Abeta peptides) according with the increase of BACE-1
and gamma-secretase activities. This retard in the APP
metabolism seemed to be directly implicated in the syn-
aptic Abeta accumulation and, in consequence, in the
pathology progression between synaptically connected
regions.Methods
Transgenic mice
Generation and initial characterization of PS1M146L/
APP751sl (PS1/APP) tg mice has been reported previo-
usly [10,58,59]. Heterozygous PS1/APP double tg mice
(C57BL:6 background) were generated by crossing homo-
zygous PS1 tg mice with heterozygous Thy1-APP751SL
mice. Only male mice were used in this work. Age-
matched non-transgenic male mice (WT) of the same
genetic background (C57BL:6) were used as controls.
Mice were first anesthetized with sodium pentobarbital
(60 mg/kg), the hippocampi were dissected and immedi-
ately frozen and stored at −80°C until use. For immunohis-
tochemistry, anesthetized mice were perfused transcardially
with a paraformaldehyde-based solution (see details below).
All animal experiments were performed in accordance with
the guidelines of the Committee of Animal Research of the
University of Seville (Spain) and the European Union
Regulations.
RNA and total protein extraction
Total RNA from mice hippocampi or cultured cells was
extracted using Tripure Isolation Reagent (Roche) as
described previously [10,11,27,58,59]. After isolation, RNA
integrity was assessed by agarose gel electrophoresis. The
yield of total RNA was determined by measuring the ab-
sorbance (260:280 nm) of isopropanol-precipitated ali-
quots of the samples. The recovery of RNA was
comparable in all studied groups (1.2-1.5 μg/mg of tissue).
The protein pellets, obtained using the Tripure Isola-
tion Reagent and isopropanol-mediated precipitation,
were resuspended in 4% SDS and 8M urea in 40 mM
Tris–HCl, pH 7.4 and rotated overnight at room
temperature to get complete protein solubilization.
Reverse transcription and real-time RT-PCR
Retrotranscription (RT) was performed using random
hexamers, 4 μg of total RNA as template and High-
Capacity cDNA Archive Kit (Applied Biosystems) fol-
lowing the manufacturer recommendations [10,27]. For
real time RT-PCR, commercial Taqman™ probes (Ap-
plied Biosystems) were used for amplification. Alterna-
tively, SYBRgreen dye and designed specific primers
were used for amplification of human APP751 (forw-
ard: 5´-GGATATGAAGTTCATCATCA-3´; reverse: 5´-
TCACTGTCGCTATGACAACA-3´), and human PS1
(forward: 5´-TGGCTCATCTTGGCTGTG-3´; reverse:
5´-ACCAGCATACGAAGTGG-3´). PCR reactions were
carried out using either ABI Prism 7000 or 7900HT se-
quence detector systems (Applied Biosystems). A stand-
ard curve was first constructed for every assay, using
increasing amounts of cDNA. In all cases, the slope of the
curves indicated optimal PCR conditions (slope 3.2-3.4).
The cDNA levels of the different mice were determined
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fication was done in parallel with the gene to be analyzed,
and this dada used to normalize target gene results.
Independent of the analyzed gene, results were always
expressed using the comparative Ct method, following
the Bulletin number 2 from Applied Biosystems. As a
control condition, we selected 6-month-old WT mice. In
consequence, the expression of all tested genes, for all
ages and mouse strains, was referenced to the expression
levels observed in 6-month-old WT mice.
Western blot
Western blots were performed as described [60]. Briefly,
5–20 μg of proteins from the different samples were
loaded on 16%-SDS-tris-tricine-PAGE or 12%-SDS-tris-
glycine-PAGE and transferred to nitrocellulose (Hybond-
C Extra; Amersham).
After blocking, using 5% non-fat milk, membranes
were incubated overnight, at 4°C, with the appropriate
antibody: phospho-neurofilament (clone SMI-31; 1:1,000;
Abcam), total-neurofilament (clone SMI-32; 1:1000;
Abcam), phospho-Ser199:202-Thr205-PHF-tau (clone
AT8; 1:1000; Pierce), phospho-Thr212-Ser214-PHF-tau
(clone AT100; 1:1,000; Innogenetics), kinesin-1 heavy
chain (1:1,000; Abcam), dynein-1 intermediate chain
(1:1000; Millipore), ATP-synthetase-Beta (1:1000; BD
Transduction Laboratories), Abeta peptide (clone 6E10;
1:5000; Signet), APP C-terminal (1:6000; Calbiochem),
PS1 C-terminal (1:2000; Millipore), BACE-1 (1:1000;
Abcam), V0a1-proton-pump subunit (1:1000; Synaptic
Systems), LC3B (1:1000; Cell Signaling), cathepsin B
(1:1000, Santa Cruz); cathepsin-D (1:5000; ABFrontier
Co. Ltd), Lamp-1 (1:1000; Developmental Studies
Hybridoma Bank; University of Iowa), ubiquitin (1:1000;
Sigma-Aldrich) and Beta-actin (1:5000; Sigma-Aldrich).
Membranes were then incubated with the correspond-
ing horseradish-peroxidase-conjugated secondary anti-
body (Dako, Denmark) at a dilution of 1:8000. Each
blot was developed using the ECL-plus detection
method (Amersham).
For quantification, the scanned (Epson 3200) images
were analyzed using PCBAS program. For normalization
purposes, proteins were first estimated by Lowry and
protein loading corrected by beta-actin. The intensity of
bands from 6-month-old WT or PS1/APP (Figures 4A,
E and F; Figures 5C and D) mice were averaged and con-
sidered as 1 relative unit. All other data were then nor-
malized by the specific signal observed in 6-month-old
WT or PS1/APP group or negative control for “in vitro”
experiments.
Enzymatic activity determination
BACE-1, Cathepsin B and D activities were determi-
ned using commercial kits (R&D Systems, Germany;Calbiochem, Germany and Sigma-Aldrich, respect-
ively) following the manufacturer instructions. Briefly,
fresh hippocampal samples were homogenized in the
buffer supplied by the manufacturer or in PBS (for
proteasome activity), centrifuged at 10,000xg (15 min
at 4°C) and the supernatant (100–200 μg of protein
per assay) was used. BACE-1 and cathepsin B and D
activities were determined using substrates provided
by the manufacturer
Proteasome chymotrypsin-like activity was determined
as described [61]. Briefly, soluble fractions (30–50 μg
of protein per assay) were diluted in 50 μM reaction
substrate Suc-Leu-Leu-Val-Tyr-aminomethylcoumarin
(AMC) (Sigma-aldrich), 0.1mM EDTA, 5mM DTT,
0.01% (w:v) CHAPS; 100mM NaCl; 1% (v:v) Glycerol,
50mM HEPES-KOH pH 7.5. Duplicated reactions
were placed in a 96-well black polystyrene microplate (BD
Transduction Labs.) and incubated at 37°C. Fluorescence
was determined at excitation 360-380nm and emission
460-480 nm.
For each enzymatic assay, the fluorescence intensity
was determined every 15 minutes (starting by the
addition of the substrate) for a 1–2 hours final incuba-
tion time, using a Synergy HT Multi-mode microplate
reader (Biotek). The activities were calculated from the
maximal slope of the fluorescence intensity vs time
curves and corrected by the amount of protein added.
The results were then normalized by the activity
observed in 6 months WT mice or 6 months PS1/APP
mice (for BACE-1).
Also for each enzymatic activity, a reaction without
substrate, a reaction without sample, and reaction with
an inhibitor were used as negative controls. The inhibi-
tors used were: Cathepsin B, Inhibitor Ref. 219385 (Call-
biochem); Cathepsin D, pepstatin A Solution Ref. P3749
(Sigma-Aldrich); Proteasome 10 μM MG-132 (Sigma-
Aldrich). Independently of the enzymatic activity assay,
each experiment was repeated, at least, three times for
each age and genotype.
Gamma-secretase activity was determined following
previously described protocols with some modifications
[62]. Briefly, membrane pellets from PS1/APP animals
(n=6 per age) were thawed and resuspended (at 3 mg of
protein per ml) in 150 mM Citrate Buffer, pH 6.4, con-
taining protease inhibitors (Roche). Aliquots (150 μg of
proteins) were used for each assay. As negative control,
100 μM L-685-458 gamma-secretase inhibitor (Calbio-
chem) was added prior assay. Samples were then incu-
bated, at 37°C with orbital shaking at 400 rpm, for 2
hours. After incubation, membranes were sonicated (at 80
W for 30 seconds) and centrifuged at 30,000xg (30 min-
utes, 4°C). Supernatants were used to determine AICD
production by western blot using anti-APP C-terminal as
primary antibody.
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After anesthesia with sodium pentobarbital (60 mg/kg),
6, 12, and 18-month-old control (WT) and PS1/APP tg
male mice (n=4/age/genotype) were perfused transcar-
dially with 0.1 M phosphate-buffered saline (PBS), pH
7.4 followed by 4% paraformaldehyde, 75 mM lysine, 10
mM sodium metaperiodate in 0.1 M phosphate buffer
(PB), pH 7.4. Brains were then removed, post-fixed over-
night in the same fixative at 4°C, cryoprotected in 30%
sucrose, sectioned at 40 μm thickness in the coronal
plane on a freezing microtome and serially collected in
wells containing cold PBS and 0.02% sodium azide. All
animal experiments were approved by the Committee of
Animal Use for Research of the Malaga University
(Spain) and the European Union Regulations.
Immunohistochemistry
Coronal free-floating brain sections (40 μm thick) from 6
and 12–18 month-old control (WT) and PS1/APP mice
were processed simultaneously in the same solutions and
conditions to prevent processing variables. Sections were
first treated with 3% H2O2/3% methanol in PBS and with
avidin-biotin Blocking Kit (Vector Labs, Burlingame, CA,
USA), and then incubated overnight at room temperature
with one of the following antibodies: anti-APP-C-terminal
rabbit polyclonal (1:20,000; Sigma-Aldrich), anti-phospho-
Ser199:202:Thr205-PHF-tau mouse monoclonal (clone
AT8; 1:500; Pierce) anti-ubiquitin rabbit polyclonal (1:2,000,
Dako), anti-LC3 goat polyclonal (1:1,000, Santa Cruz
Biotechnology), anti-BACE-1 rabbit polyclonal (1:1,000,
Abcam) or anti-Lamp2 rabbit polyclonal (1:500, Abcam).
The tissue-bound primary antibody was detected by
incubating with the corresponding biotinylated second-
ary antibody (1:500 dilution, Vector Laboratories), and
then followed by streptavidin-conjugated peroxidase
(Sigma Aldrich) diluted 1:2000. The reaction was visua-
lized with 0.05% 3-3’-diaminobenzidine tetrahydrochlor-
ide (DAB, Sigma Aldrich), 0.03% nickel ammonium
sulphate and 0.01% hydrogen peroxide in PBS. When
required, immunolabeled sections were then incubated
for 3 minutes in a solution of 20% Congo red. Sections
were then mounted on gelatin-coated slides, air dried,
dehydrated in graded ethanols, cleared in xylene and
coverslipped with DPX (BDH) mounting medium. Speci-
ficity of the immune reactions was controlled by omit-
ting the primary antiserum.
Quantitative analysis of Abeta plaques-associated
dystrophic neurites
The number of APP-immunopositive dystrophic neurites
per plaque was quantified over Congo red stained Abeta
deposits in sections from PS1/APP animals at young
(4 and 6 month-old group) and old (12 and 18 months-
old group) ages (n= 6/group; 5 sections per animalthrough the antero-posterior extent of the hippocam-
pus). Quantification was done in CA1 subfield which
was defined using a 10x objective and the number of
dystrophic neurites was counted using a 100x objective
in an Olympus BX61 microscope equiped with New-
CAST software package (Olympus, Glostrup, Denmark).
All plaques present in the CA1 region of each section
were quantified. The number of dystrophic neurites per
plaque was normalized to the mean plaque area to allow
comparisons between groups.
Synaptosome and microsome fractions isolation
Synaptosomal fractions were obtained basically as
described previously [17,63]) with some modifications.
Briefly, one mouse hemicortex was gently homogenized
with a glass Dounce homogenizer in cold Buffer A (0.32
M sucrose, 1 mM EDTA, 1mM EGTA in 20 mM Tris–
HCl pH 7.5, plus 1mM sodium orthovanadate, 50 mM
sodium floride and a complete protease inhibitor cock-
tail (Roche) at a ratio of 40-50 mg of tissue per ml of
buffer. This homogenate was first centrifuged at 1500 g
and the post-nuclear supernatant was again centrifuged
at 12,600 g for 20 minutes at 4°C to get the crude synap-
tosomes fraction. This pellet was resuspended in 13%
(w:v) (final concentration) Ficoll PM400 (in buffer A)
and layered on the bottom of a discontinuous gradient,
composed by buffer A and 7% Ficoll (in buffer A). The
gradient was centrifuged at 100,000g (45 minutes, 4°C)
in a TLS-55 swimming bucket rotor (Beckman-Coulter),
and synaptosomes were isolated at the 7.5–13% inter-
face. After washing (twice with buffer A), the pellet of
synaptosomes was resuspended in Buffer A. The possible
contamination with vacuolated postsynapses was evalu-
ated by testing the presence of tau (presynaptic) and
MAP2 (postsynaptic) proteins. Results (not shown) indi-
cated the existence of a minimal contamination with
vacuolated postsynapses.
On the other hand, the microsomal fraction was
obtained after additional centrifugation of the 12,600 g
supernatant at 100,000 g (1 hour, 4°C) in a TLA-110
rotor (Beckman-Coulter). The pellet of microsomes was
also resuspended in Buffer A. The protein content of the
both synaptosomal and microsomal fractions was deter-
mined by Lowry.
APPswe-expressing N2a cultures
APPswe-stably transfected Neuroblastoma cells were gen-
erously donated by Dr. Gopal Thinakaran (University of
Chicago) [35]. N2aAPPswe cells were cultured in high
glucose DMEM-Optimem (50%-50%) supplemented with
2 mM glutamine and 5% fetal bovine serum (PPA
Company), in presence of Penicillin and Streptomycin
(100 units/ml and 0.01 mg/ml respectively) and G418
(PPA Company) as clonal selection antibiotic (0.2 μg/ml)
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tion of Chloroquine diphosphate salt (Sigma-Aldrich) or
MG132 (Sigma-Aldrich) were diluted in the same media
at a final concentration of 10 or 5 μM, respectively. This
media was kept for 6 or 24 hours before collecting the
cells and isolating RNA and protein as described above.
Statistical analysis
Data were expressed as mean ± SD. The comparison be-
tween two mice groups (WT and PS1/APP mice) was
done by t test. For comparison between several age
groups, we used one-way ANOVA followed by Tukey
post hoc multiple comparisons test (Statgraphics plus
3.1). As stated above, for most experiments, the different
xgroups were compared with 6-month-old WT mice. In
some cases (Figures 4A, E and F; Figure 5C and D)
6-month-old PS1/APP mice were used as reference. The
significance was set at 95% of confidence.
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